Related references
Note: Only part of the references are listed.WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
Ryu Yanagisawa et al.
ANTICANCER RESEARCH (2018)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
Lisa A. Kottschade
CURRENT ONCOLOGY REPORTS (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Biomarkers for Clinical Benefit of immune Checkpoint inhibitor Treatment-A Review From the Melanoma Perspective and Beyond
Kristina Buder-Bakhaya et al.
FRONTIERS IN IMMUNOLOGY (2018)
Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
Elisa A. Rozeman et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab
Patrick Roth et al.
NEURO-ONCOLOGY (2017)
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Robert J. Torphy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
Chengshi Wang et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
Tiffany R. Hodges et al.
NEURO-ONCOLOGY (2017)
RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143
D. A. Reardona et al.
NEURO-ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
Abhishek D. Garg et al.
TRENDS IN IMMUNOLOGY (2017)
Immune Checkpoint in Glioblastoma: Promising and Challenging
Jing Huang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Trial watch: Immune checkpoint blockers for cancer therapy
Claire Vanpouille-Box et al.
ONCOIMMUNOLOGY (2017)
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
Anna Laurell et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Adjuvant therapy in renal cell carcinoma
Francesco Massari et al.
CANCER TREATMENT REVIEWS (2017)
MSH2 Loss in Primary Prostate Cancer
Liana B. Guedes et al.
CLINICAL CANCER RESEARCH (2017)
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A. Batich et al.
CLINICAL CANCER RESEARCH (2017)
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
Kalijn F. Bol et al.
ONCOIMMUNOLOGY (2016)
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
Kalijn F. Bol et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model
Lydia Dyck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
Angela Vasaturo et al.
CANCER RESEARCH (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
Luping Zhang et al.
RADIATION ONCOLOGY (2016)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Tanner M. Johanns et al.
CANCER DISCOVERY (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
Steve Boudewijns et al.
ONCOIMMUNOLOGY (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma
Robert A. Figlin
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases
Sofie Wilgenhof et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
Julien Fourcade et al.
CANCER RESEARCH (2014)
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Lidia Robert et al.
CLINICAL CANCER RESEARCH (2014)
Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
Lawrence Fong et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Clinical use of dendritic cells for cancer therapy
Sebastien Anguille et al.
LANCET ONCOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Tumoricidal activity of human dendritic cells
Jurjen Tel et al.
TRENDS IN IMMUNOLOGY (2014)
A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
Hirokazu Matsushita et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)lL17(+) response
Michael R. Olin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo
Miki Tongu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
Nadeem A. Sheikh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
Dennis Lindau et al.
IMMUNOLOGY (2013)
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Satoshi Wada et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go
Angela Vasaturo et al.
FRONTIERS IN IMMUNOLOGY (2013)
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Hilko Ardon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma
Erik H. J. G. Aarntzen et al.
CANCER RESEARCH (2012)
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
Richard C. Koya et al.
CANCER RESEARCH (2012)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients
Sergiusz Markowicz et al.
MEDICAL ONCOLOGY (2012)
Impact of tumour volume on the potential efficacy of therapeutic vaccines
J. L. Gulley et al.
Current Oncology (2011)
Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
Andreas Draube et al.
PLOS ONE (2011)
TGF beta, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
L. Yang
CURRENT MOLECULAR MEDICINE (2010)
Biology of interleukin-10
Robert Sabat et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Modulating numbers and phenotype of CD8+ T cells in secondary immune responses
Thomas C. Wirth et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2009)
Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients
Aude Bonehill et al.
CLINICAL CANCER RESEARCH (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Ecto-calreticulin in immunogenic chemotherapy
Michel Obeid et al.
IMMUNOLOGICAL REVIEWS (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy
Benjamin F. Johnson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
S Verma et al.
CANCER (2006)
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome
IJM de Vries et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
LM Liau et al.
CLINICAL CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination
CJ Wheeler et al.
CLINICAL CANCER RESEARCH (2004)
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
CT Garnett et al.
CANCER RESEARCH (2004)
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
M Chakraborty et al.
JOURNAL OF IMMUNOLOGY (2003)
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells
B Schuler-Thurner et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Extraneural metastases of primary brain tumors
T Schweitzer et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Share Paper
